Member Info for Richard08

We are only a couple of months off an announcement on ‘mistral’ now. Hopefully it’s all on schedule. Fingers crossed, we will look back at this as the bottom with the company now having sufficient funds to see it through to profitability.

https://www.cityam.com/hunt-pledges-20bn-for-carbon-capture-and-nuclear-ramp-up-in-clean-energy-push/

Always a possibility something will come our way. With the IRA supporting the company in the US it would be good to have something on home turf that encourages investment in green tech. Not just for IES but for the sake of the planet too.

Some good news to follow on from the bad of the placing. Say what you like, the new orders are fast coming down the pipe! We just need mistral to launch now and we’re off!

You're not alone Phyl... I'm here. I have this down as a long term income and growth come back in twenty years type of stock.
Having said that I think this is down to the recent fairly watered down Chinese govt growth targets. Add to that the hostile noises coming out of the US towards China and the sentiment towards China is not good. At least for the moment. But today's dead fish is tomorrow's valuable salmon so I'm hanging in until sentiment shifts again!

Could be almost anything... Sudan isn't exactly winning in the 'good nation' category but there's nothing new there. Dollar is going up which is going to affect gold price. And if you zoom out on the PAF share price then it does take big dips periodically and stay in the doldrums for a year or two. Maybe we are just due a drop? Longer term though, company seems sound. African problems have always been there in some shape of unstable government or other and so hold and pound-cost-average if you can I would argue.

I’m here Ed1Mil, what do you think of the results? Seem impressive to me. No mention of any slow down or recession/inflation fears in the RNS but I will be watching the presentation on Thursday to see if they get a mention. I will be interested to see what management think about the macro situation the UK is in an whether they are worried.

Just a reminder of the recent trading update...

''Highlights

· Total revenue is expected to increase by 24.0% to $24.5m (2021: $19.7m) (up 25.6% to $24.8m at constant currency), in line with expectations, with each of the divisions showing revenue growth of over 20%.

· We are delighted to have achieved an adjusted EBITDA profit for the fourth quarter of 2022. This aligns with the Board's expectations and gives us great confidence about the future.

· Healthy cash position at 31 December 2022 of $5.9m (H1 2022: $6.2m; year-end 2021: $7.7m) supports the current business growth plan.''

Any meat they can put on those bones will make wonderful reading. The recent flat-lining of the sp can be put down to all sorts of things, the market is giving nothing the benefit of the doubt at the moment and this is still a recently-profitable biotech on AIM. It will have to remain profitable (and there's no reason why it shouldn't!) But if Danny and Dave can spell out how a decent growth rate can be maintained then in time the market will re-rate it.

I for one do not see an RNS from TRX and have my blood run cold anymore!

Thanks for your insights bluerill, good to have you on the share chat.

Thanks all for your thoughts. Interesting to hear different insights/angles on this. It will be interesting to see, going forward, if anyone takes the fall for this and if there is some shuffling of bums on seats after a decent interval.

Am I missing something in the joined up thinking dept? Why take out the loan at all? Why didn’t they just do a fundraiser in December and avoid early repayment charges etc?

Page ten of the Business and Money section if you’re looking. Positive article suggesting a buy. Could bring some attention our way on Monday morning. Either way, good to get some positive PR.

'It landed after market hours Richard.'

Also a side effect of skim-reading the days RNSs at the end of the day! LOL

As you guys mention, at least it's out of the way and the company is funded through whatever means until the commercialisation of 'mistral'. The launch for which is due this May if deadlines are met. A question mark over the companies continued viability is removed. Although I am now typing this after a mid-week cider so God-knows what level of accuracy I'm giving to this!

I would have expected more discussion on today’s RNS… maybe everyone is just reading it over their tea as am I! Seems a positive RNS on the whole, the sp has not dropped to the offering price and I for one will be buying more if allowed and if it is still at a discount when the offering comes through.

Definitely a good set of results. I imagine the ‘boring’ nature of this one doesn’t get people’s blood going… the possibility of a windfall tax hangs over TRIG for many would-be-investors perhaps. But if that doesn’t materialise the the sp will bounce for sure.

Agree with all that grippa. And with today's update there is no reason to question the investment decision in my mind. An absolute steal at these prices and with CEO skin in the game it should be a good investment and divi payer for years to come.

Nice little find. The more mainstream discussion there is about VRFBs the more they are accepted and understood which should only increase deployment.

Possibility here that the sp has bottomed out and beginning to look for a reason to go up? Pure speculation of course but this has fallen a long way and with a P/S now just under two and averaging 17-22% growth over the last three to five years, the recent suggestions that a UK recession may not be as bad may finally be pushing this up. Of course what we really need is a positive trading update… fingers crossed it comes soon.

Lots to be happy with there. The line that keeps me here though it:

‘We plan to initiate more than thirty Phase III trials this year, of which ten have the potential to deliver peak year sales over one billion dollars.’

Investing for the future of the company and my small bit of it!

https://www.proactiveinvestors.co.uk/companies/news/1004781/tissue-regenix-broker-initiates-coverage-with-1-2p-price-target-1004781.html

Always good to have a new broker or two.

Ten years? Crikey you’ve had quite a ride Jurado! I’ve been a shareholder since 2020 here and even in that time it’s gone up to 0.8p and down to 0.37. For you to hold through ten years of that and worse is a credit to you. Hopefully now with the company finally in the green your patience will be rewarded.